You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Automated point-of-care identification of innocent Still's murmur in children
SBC: AUSCULTECH DX LLC Topic: NHLBIPROJECT SUMMARY The overall goal of the proposed research and technology transfer effort is to develop a low-cost, point-of-care, mobile device-based technology for automated identification of Stillandapos;s murmur, the most common innocent (benign and harmless) heart murmur of childhood. This novel technology could reduce the current rate of over half a million children unnecessarily referred to ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Mobile Peer Support for Opioid Use Disorders: Refinement of an Innovative Machine Learning Tool
SBC: BEACON TECH INC Topic: R41PROJECT SUMMARY This proposal develops a novelartificial intelligenceAIenabledmobile treatment delivery method that fulfills the need for a robustsecuretechnology based peer support platform to support patients with opioid use disordersOUDsThe majority of individuals with OUDs in the United States do not receive any formal substance use treatmentand growing evidence suggests that many OUD patients ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: R41Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of OCF001 for Treatment of Yeast Infections
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid Development of a Highly Specific Dengue Diagnostic Test
SBC: Z-Quick, LLC Topic: NIAIDProject Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies
SBC: 7 Hills Pharma LLC Topic: NIAIDLeukocyte adhesion deficiency type ILADis a rare and often fatal primary immunodeficiencyIt is caused by autosomal recessive mutations in the gene ITGBwhich encodes CDthe commonsubunitof thefamily of integrin cell adhesion molecules that are specifically expressed on cells of hematopoietic origin like leukocytesAs a result of decreased function ofintegrinsleukocytes cannot extravasate from the vas ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
AHTP-comet: development of an automated, high throughput comet assay system
SBC: ENGINEERING RESOURCES GROUP INC Topic: NIEHSPROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel accurate therapy for Multiple Sclerosis
SBC: Autoimmunity Biologic Solutions, Inc. Topic: NIAIDPROJECT SUMMARY Multiple SclerosisMSis the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous systemresulting in progressive neurological dysfunctionUp to datethere is no cure for the disease and current available treatments focus on preventing future immunological attacksprimarily by su ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health